# NCT02279433 (NCT02279433)

> A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

No report yet. It can be ordered.

- Drugs tested: taletrectinib
- Indication: metastatic and/or unresectable solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02279433
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Nuvation Bio Inc.
- Conditions: Solid Tumors
- Interventions: DS6051b
- Enrollment: 46
- Primary outcome: Part 1: Number of participants with dose-limiting toxicities
- Primary outcome: Tumor response

## Indexed commentary on NCT02279433 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02279433
